Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 9 of 9 for “"Nilotinib"”.
-
Ocorrência de eventos adversos relacionados a inibidores de tirosina quinase de primeira e segunda geração : revisão de literatura
… inhibitors second generation, dasatinib, and nilotinib. In this study, the recent li terature data were analyzed four years related adverse events associated with imatinib, dasatinib, and nilotinib. They were found 152 articles, of which 24 were used international articles are available online …
-
Expression and function of drug transporters in primitive CML cells
… that at therapeutic concentrations (5μM) IM and nilotinib both inhibited ABCG2 and MDR1 and nilotinib also inhibited MRP1. Neither drug was a substrate for any of the transporters. In contrast, dasatinib was shown to be a substrate for ABCG2 and MRP1, but had no effect on MDR1. Therefore activity …
-
Prognostic markers associated with tyrosine kinase inhibitor treatment response and maintenance of treatment free remission in chronic myeloid leukaemia
… dose escalation, followed by switching to nilotinib, in patients who fail to achieve time dependent molecular responses. This study also examined the effectiveness of increasing imatinib dose in patients with serum trough levels <1000 ng/mL, a threshold thought to be necessary to achieve …
-
Evolução da leucemia mielóide crônica frente à terapia com inibidores de tirosina cinase.
… ib (Glivec ® ), Dasatinib (Sprycel ® ) and Nilotinib (Tasigna ® ) that are used by chemotherapy patients with Chronic Myeloid Leukemia (LMC) . This study aims to review information about CML and treatment progress against ITK
-
Modulation of heme oxygenase-1 activity by novel synthetic compounds for pharmacological applications
… in new HO-1 hybrids: 5-fluorouracil (5-FU) and nilotinib (NIL). Particularly, 5-FU was combined with 1-(3-bromophenyl)-2-(1H-imidazol-1-yl)ethanol, a potent HO-1 inhibitor, to develop a novel 5-FU mutual prodrug. Finally, NIL was used as the structural backbone for new TK/HO-1 hybrid inhibitors …
-
Discovery of Dihydroartemisinin and Dasatinib Drug Combination to Cure Pooroutcome BCR-ABL+ Acute Lymphoblastic Leukemia
… inhibitors (BCR-ABL–KIs) imatinib, dasatinib and nilotinib induce prolonged remissions in CML but poor leukemia-reduction and relapse-control in Ph+ ALL. The relative primary BCR-ABL–KI-resistance in Ph+ ALL patients carrying predominantly BCR-ABLWT disease cannot be attributed to drug-resistant …
-
Analysis of Out-of-Pocket Expenditures of Oral Oncologics for Tennessee Recipients of Medicare Part D
… erlotinib, dasatinib, sunitinib, vorinostat, nilotinib, and lapatinib, the annual out-of-pocket costs for each drug varied from $0 to a maximum of $1,133, based on plan design. Bivariate regression analysis showed that monthly premiums, deductibles, and cost-sharing are all precise predictors …
-
The analysis of Bcr-Abl—Nox signalling in chronic myeloid leukaemia
Chronic Myeloid Leukaemia (CML) is a myeloproliferative disorder characterised by increased proliferation of haematopoietic stem cells. CML results following generation of the chimeric protein Bcr-Abl, a constitutively active tyrosine kinase which induces oncogenesis in part by promoting increased …